velmanase alfa
Selected indexed studies
- ** (, 2023) [PMID:40258107]
- Velmanase Alfa-tycv. (Am J Health Syst Pharm, 2023) [PMID:37140690]
- Can velmanase alfa be the next widespread potential therapy for alpha-mannosidosis? (Int J Surg, 2023) [PMID:37352513]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- PMID:40258107 (2023) pubmed
- Velmanase Alfa-tycv. (2023) pubmed
- Can velmanase alfa be the next widespread potential therapy for alpha-mannosidosis? (2023) pubmed
- Extended long-term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha-mannosidosis. (2025) pubmed
- Velmanase alfa approved for treatment of non-central nervous system manifestations of alpha-mannosidosis: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). (2024) pubmed
- Alpha-Mannosidosis. (1993) pubmed
- Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis. (2018) pubmed
- Early biochemical effects of velmanase alfa in a 7-month-old infant with alpha-mannosidosis. (2020) pubmed
- Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. (2018) pubmed
- Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis: A phase 2, open label, multicenter study. (2023) pubmed